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In Japan, prostate cancer is treated with non-steroidal anti-androgen (flutamide and bicalutamide).
Development of breast pain during bicalutamide treatment, in prostate cancer patients reduces their quality
of life (QOL) and treatment compliance. We studied the safety and effectiveness of switching from
bicalutamide to flutamide in 13 prostate cancer patients who developed breast pain during bicalutamide
treatment. We estimated the change in breast pain using a face scale and the Expanded Prostate Cancer
Index Composite (EPIC) and EPIC-hormone domain (HD) score. The switch to flutamide relieved breast
pain in nine patients, had no effect in one patient, and increased breast pain in two patients. One patient
dropped out. Furthermore, summary score and hormone function were improved with a significant
difference in the EPIC-HD score. Switching to flutamide in prostate cancer patients who develop breast
pain during bicalutamide is safe and effective.
(Hinyokika Kiyo 60 : 17-23, 2014)
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Fig. 1. Assessment method of breast pain. Breast pain was assessed on both a 0- to
5-point face scale and 0- to 10-point EPIC-HD scale. The maximum





回 (125 mg/day) で投与開始した．投与開始 1週間後
に再度肝機能検査を行った．肝機能検査異常が認めら




（ 0∼ 5 点の 6 段階評価）と EPIC-HD (Expanded
Prostate Cancer Index Composite-Hormone Domain) の
QOL 調査の一部（問27と問31イ）の合計点数（ 1∼
10点の10段階評価）を，投与変更前と投与開始 5，




内ホルモンに関連する QOL 調査 (EPIC-HD) 指標と
して評価に用いた．評価方法としては，13週の時点で
face scale における乳房痛または EPIC-HD の QOL 調
査が改善（点数が減少）すれば総合的に改善したと定
義した (Fig. 2）．一方， 5週・ 9週後連続で悪化を認
める時は治療継続を中止とした．
副次評価項目として次に述べる 3 項目とした．○1
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EPIC-HD
stable Improvement Stable Worsening
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Fig. 2. Valuation method of breast pain improve-
ment. All cases were assessed by face scale
and EPIC-HD. Pain was rated on a 0- to
5-point face scale and a 0- to 10-point EPIC-
HD scale. Both assessments were divided
into three categories (improvement, stable,
and worsening). Lower and higher scores
corresponded to improvement and wors-
ening assessments, respectively.
総合得点 (summary score) 11項目 ; 問26∼31（ア∼
カ），ホルモン下位尺度であるホルモン機能 (HF :
hormone function) 5 項目 ; 問26∼30，ホルモン負担
感 (HB : hormone bother) 6項目 ; 問31（ア∼カ）に
分けてスコアリングを行った6)．スコアリングの数値
が高くなるほど，QOL 改善を示すことになる．○2 投













































































































ア）ほてり ▼ 0……… 1……… 2……… 3……… 4……… 5
イ）乳首やそのまわりがはれたり，痛む ▼ 0……… 1……… 2……… 3……… 4……… 5
ウ）体毛がうすくなる ▼ 0……… 1……… 2……… 3……… 4……… 5
エ）気分の落ち込み ▼ 0……… 1……… 2……… 3……… 4……… 5
オ）活力が足りない ▼ 0……… 1……… 2……… 3……… 4……… 5
カ）体重の変化 ▼ 0……… 1……… 2……… 3……… 4……… 5
Fig. 3. Assessment method of EIPC-HD’s QOL. These questions were used to assess EPIC-HD’s QOL. hormone
function (HF) was assessed by questions 26-30 and hormone bother (HB) was assessed by question 31. Total
score was the sum of scores on all questions. The original EPIC scale score was converted to the assessment
score.





B1 : 6例，B2 : 1例，C1 : 5例，C2 : 1例，前立腺癌




PSA : 1.25±1.21 ng/ml (0.008∼3.43 ng/ml) であっ
Table 1. Clinical characteristics of 13 prostate cancer patients who developed breast pain during bicalutamide
treatment










1 71 C2 T3bN0M0 3＋4 19.7 Op 119 0.36
2 59 C1 T3aN0M0 3＋4 16.3 Op/RT 1,338 1.97
3 69 C1 T3bN0M0 4＋5 18.9 Op 904 0.02
4 69 C1 T3aN0M0 3＋4 10.2 Op/RT 406 0.25
5 74 B2 T2bN0M0 3＋2 10.4 Op 1,155 0.34
6 67 B1 T2aN0M0 3＋3 7.8 Op 1,164 0.01
7 78 B1 T2aN0M0 3＋3 9.9 None 275 1.31
8 83 B1 T2aN0M0 3＋3 10.5 None 287 3.43
9 63 C1 T3bN0M0 4＋3 9.0 Op/RT 773 0.33
10 79 B1 T2aN0M0 3＋3 11.8 None 154 2.99
11 79 B1 T2aN0M0 3＋3 6.2 None 238 1.48
12 76 B1 T2aN0M0 3＋3 26.0 Op 154 0.008
13 78 C1 T3aN0M0 3＋3 10.4 None 181 3.28
GS : Gleason score, Op : Operation, RT : Radiation therapy.





Entry 5 W 9 W 13 W Assessment Entry 5 W 9 W 13 W Assessment
1* 2 2 2 ― Drop out 5 8 3 ― Drop out Drop out
2 3 1 1 1 Improvement 6 5 2 2 Improvement Improvement
3 4 4 4 4 Stable 9 9 7 9 Stable Stable
4 2 2 5 2 Stable 9 7 10 7 Improvement Improvement
5 1 1 1 0 Improvement 3 5 1 2 Improvement Improvement
6 2 3 2 2 Stable 6 7 4 5 Improvement Improvement
7 2 1 1 1 Improvement 6 5 3 3 Improvement Improvement
8 2 2 1 1 Improvement 8 4 4 2 Improvement Improvement
9 2 2 2 2 Stable 4 7 4 7 Woresing Woresing
10 2 2 2 3 Woresing 3 10 5 5 Woresing Woresing
11 1 1 1 1 Stable 6 7 5 3 Improvement Improvement
12 4 2 2 1 Improvement 9 9 4 5 Improvement Improvement
13 3 2 2 1 Improvement 9 5 4 3 Improvement Improvement
The overall assessment was a composite of both the face scale and EPIC-HD results and compared the time for 13 weeks with a baseline
(Refer to Fig. 1). * Case 1, judge assessment of breast pain was not possible, because he had chronic diarrhea, and stopped taking






乳房痛の改善評価は，face scale では13例中 6例改
善，不変 5例，悪化 1例，脱落 1例であった．EPIC-
HD の QOL 調査では13例中 9例改善，不変 1例，悪
化 2 例，脱落 1 例であった．Face scale と EPIC-HD
の QOL 調査との評価乖離は認めなかった．最終的な
総合評価では13例中 9例改善，不変 1例，悪化 2例，
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メインである summary score，ホルモン機能 (HF），ホ
ルモン負担感 (HB) は共にスコアは上昇しており，













13 weeks 90.9 (63.6-93.2)
EPIC-HD’s QOL score consisted of the hormonal score
(summary score) and two subscales (hormonal function and
hormonal bother). Response options for each EPIC item
formed a Likert scale, and multi-item scale scores were
transformed linearly to a 0 to 100 scale, with higher scores
representing better QOL. The QOL scores at entry were
compared with those at flutamide treatment (13 weeks later)
(Wilcoxon signed-ranks test).
泌60,01,04-4
Fig. 4. PSA level during flutamide treatment. This line chart shows PSA level during flutamide treatment.
* In this case (case 8), we found PSA biochemical recurrence, but, PSA level declined after this study.
The patient continues to receive flutamide treatment.
summary score および HF では統計学的な有意差を
もって QOL の改善を認めた (Table 3）．○2 PSA 値の




ルしている．○3 CTCAE v 3.0 による安全性評価では，
AST/ALT 共に上昇なく，肝障害を認めたものはな















































Fig. 5. The mechanism of breast pain and gynecomastia affected by adrenal androgen. ER-
induced breast pain and gynecomastia in (B) is the result of reaction of adrenal
androgens (DHEA-S, DHEA and Androstenediol) with estrogen receptor (ER). E1 :
estrone, E2 : estradiol, E1S : estrone sulfate, DHEA-S : dehydroepiandrosterone
sulfate, DHEA : dehydroepiandrosterone, DHT : dehydrotestosterone, AR : androgen
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RECHALLENGE OF EVEROLIMUS FOR METASTATIC RENAL
CELL CARCINOMA AFTER RECOVERY FROM GRADE 3
INTERSTITIAL LUNG DISEASE : A CASE REPORT
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Takuya Okada1, Koei Muguruma1 and Mutsushi Kawakita1
1The Department of Urology, Kobe City Medical Center General Hospital
2The Department of Respiratory Medicine, Kobe City Medical Center General Hospital
We report a case of the rechallenge of everolimus for metastatic renal cell carcinoma (RCC) after
successful recovery from grade 3 interstitial lung disease (ILD). A 76-year-old man with metastatic RCC
developed grade 3 ILD one month after the initiation of everolimus therapy (10 mg/day). ILD subsided in
4 months after the withdrawal of everolimus and treatment with corticosteroids. Half dose (5 mg/day) of
everolimus was rechallenged for 9 months until another grade 3 ILD developed. Everolimus kept the
disease under control for 13 months including the discontinuation period.
(Hinyokika Kiyo 60 : 25-28, 2014)














患 者 : 76歳，男性















ス 10 mg/day 投与開始． 9 月，発熱，咳嗽を認め受
診．KL-6 475 U/ml（基準値 ＜500 U/ml），WBC 5,400/
μl，CRP 2.0 mg/dl．間質性肺疾患の可能性を考えエ
ベロリムス 5 mg/day に減量． 1週間後，CT 上間質
性肺疾患を認め緊急入院となった．
入院時検査所見 : 体温 38.8°C，KL-6 573 U/ml，
SP-D 151 ng/ml（基準値 ＜110 ng/ml），WBC 4,400/
μl，CRP 3.4 mg/dl．
画像所見 : CT 上両側下肺野に浸潤影を認めた
(Fig. 1）．
入院後経過○1 : 2日目からエベロリムス中止． 3日
泌尿紀要 60 : 25-28，2014年 25
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Fig. 1. A CT image before the initiation of everolimus treatment (left) and one month later
(first admission, right).




好中球 3％，好酸球 2％，CD4/CD8 5.1 であり薬剤
性肺障害として矛盾しなかった．発熱の持続，胸部レ
ントゲン上陰影の悪化を認めたため 6日目からプレド
ニゾロン内服 (35 mg/day) を開始した．その後速や
かに解熱し画像上陰影の改善を認めたためプレドニゾ
ロン漸減，23日目退院となった．
退院後経過○1 : 入院後 2カ月で KL-6 は正常化，入
院後 3カ月の CT では間質性肺疾患像は消失してお
り，局所および転移巣は変化していなかった．2011年
1月，エベロリムス 5 mg/day で再開．2011年 5月，
漸減してきたプレドニゾロン内服中止 (35 mg× 4日，
30 mg× 5 日，25 mg×26日，20 mg×63日，15 mg×
28日，10 mg×49日，7 mg×28日，5 mg×57日）と
なった． 6月の CT で局所および転移巣に変化なかっ
たが， 7月，KL-6 587 U/ml と高値を認めエベロリム
スを中止した． 8 月，KL-6 518 U/ml と依然高値で
あったが CT 上間質性肺疾患認めず新たに肝転移を認
泌60,01,05-2-1 泌60,01,05-2-2
Fig. 2. A CT image before the rechallenge of everolimus (left) and 9 months after rechallenge
(second admission, right).





入院時検査所見 : 体温 39.1°C，WBC 12,500/μl，
CRP 5.36 mg/dl．
画像所見 : CT 上左肺下葉に浸潤影あり，転移巣に
変化なし (Fig. 2）．
入院後経過○2 : 1日目よりエベロリムス中止．低酸




球 1％，CD4/CD8 4.4 であり薬剤性肺障害として矛
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Fig. 3. Clinical course during everolimus therapy.
た．2012年12月永眠された．プレドニゾロンに関して
は漸減し中止可能だったが，緩和医療の意味も含め 5
mg/day 内服を継続 (30 mg× 7日，20 mg× 7日，15
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